Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01866943 · ClinicalTrials.gov registry record · Phase 2
Role of Topical Tranexamic Acid in Total Hip Arthroplasty
A Phase 2 study, sponsored by Northwell Health.
- Terminated
- Registry status
- Phase 2
- Development phase
- 41
- Enrollment target
NCT01866943: Clinical Trial Phase 2 study, sponsored by Northwell Health.
NCT01866943 is a Phase 2 study that was terminated before completion, run by Northwell Health. The registered enrollment target is 41 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01866943, a Phase 2 study, was terminated before completion, sponsored by Northwell Health.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 41 participants
- Enrollment target
Study Summary
Total hip arthroplasty (THA) is a procedure associated with perioperative blood loss, requiring blood transfusions in some patients. The major cause of this blood loss is due to surgical trauma that induces the clotting cascade and fibrinolysis. Several previous studies and meta-analyses have shown that tranexamic acid is an effective antifibrinolytic agent that reduces blood loss in a variety of situations. Tranexamic acid given in an intravenous form has been extensively studied and shown to be efficacious in cardiothoracic, spine surgical procedures as well as total knee arthroplasty (TKA) and THA. Similarly, topical tranexamic acid has been associated with decreased blood loss in cardiac surgeries as well. Recently, results from a prospective randomized study on the topical use of tranexamic acid in total knee arthroplasty found it to be effective for reducing postoperative blood loss. Taking all of the above into consideration we have proposed a study to evaluate effects of topical application of tranexamic acid on postoperative blood loss and blood transfusion on patients undergoing total hip arthroplasty. The aim of this study is to evaluate the efficacy of the topical application of tranexamic acid on blood loss in patients undergoing a primary unilateral total hip arthroplasty.
Primary Outcome
Estimated Blood Loss defined as Pre Op Hgb mins the Post Op Day two Hgb.
Interventions
- DRUG Tranexamic Acid
- DRUG Normal Saline Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2011-11 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Why NCT01866943 stopped before completion
NCT01866943 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 41 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 2 interventions - of which Tranexamic Acid is the first listed.
NCT01866943 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01866943 about?
NCT01866943 is a clinical study titled "Role of Topical Tranexamic Acid in Total Hip Arthroplasty". Total hip arthroplasty (THA) is a procedure associated with perioperative blood loss, requiring blood transfusions in some patients. The major cause of this blood loss is due to surgical trauma that induces the clotting cascade and fibrinolysis. Several previous studies and meta-analyses have shown ...
What is the current status of trial NCT01866943?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 41 participants. The study started on 2011-11. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01866943?
The interventions under investigation include: Tranexamic Acid (DRUG), Normal Saline Solution (DRUG).
Who is sponsoring clinical trial NCT01866943?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01866943's enrollment target sits among peer trials
41 1352nd of 2000 higher than 639 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03449238 · 41 participants · Phase 1
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients
- NCT03900793 · 41 participants · Phase 1
Losartan + Sunitinib in Treatment of Osteosarcoma
- NCT04082520 · 41 participants · Phase 2
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
- NCT04220190 · 41 participants · Phase 2
RAPA-501 Therapy for ALS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia